On Feb 14, 2019 Gritstone Oncology Inc (NASDAQ:GRTS) Shorts Increased By 154.65%

Gritstone Oncology Inc (NASDAQ:GRTS) recorded an increase of 154.65% in shorted shares. FINRA announced in February GRTS’s total 890,500 shorted shares. The 349,700 previous shares are up with 154.65%. With Average volume 137,100, GRTS’s former position will take 7 days to recover.

GRTS is reaching $12.02 during the last trading session, after decreased 5.28%.Gritstone Oncology, Inc. has volume of 63,890 shares. Since February 14, 2018 GRTS has 0.00% and is . GRTS the S&P 500 by 0.00%.

Gritstone Oncology Inc. is engaged in the discovery and development of cancer immunotherapies.The firm is valued at $349.04 million. The firm focuses on developing tumor-specific neo-antigens therapies for non-small cell lung cancer.Last it reported negative earnings. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc.

For more Gritstone Oncology, Inc. (NASDAQ:GRTS) news posted recently go to: Barrons.com, Seekingalpha.com, Nasdaq.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “Intraday Update: Dow Gains 110 Points as Divergence With Nasdaq Gets Worrisome – Barron’s” posted on March 16, 2018, “U.S. IPO Weekly Recap: 12 IPOs Wrap Up Active Third Quarter As SurveyMonkey Pops 34% – Seeking Alpha” on September 29, 2018, “Gritstone Oncology Announces Publication in Nature Biotechnology of Neoantigen Identification Capabilities of its Artificial Intelligence Platform, EDGE – Nasdaq” with a publish date: December 17, 2018, “Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering – Benzinga” and the last “Premarket analyst action – healthcare, sell-siders bullish on Gritstone Oncology – Seeking Alpha” with publication date: October 23, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.